Clinical Trials Logo

Clinical Trial Summary

In previous phase 2 studies, pemetrexed has shown antitumor activity in advanced non-small cell lung cancer as a single agent as well as in combination with cisplatin. Since the introduction of vitamin supplementation, pemetrexed has shown good tolerance and high safety. Vitamin supplementation has opened the opportunity to offer patients higher pemetrexed dosing, as has been demonstrated by a recent Phase 1 study. The higher dose with supplementation may increase pemetrexed's efficacy without unduly compromising safety. The present Phase 2 study will use pemetrexed dosing that is tailored to individual patient tolerance, and is an effort to determine the efficacy and safety of this approach in patients with advanced NSCLC who had prior chemotherapy.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00190840
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 2
Start date September 2003
Completion date October 2005

See also
  Status Clinical Trial Phase
Recruiting NCT04486833 - Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib Phase 1/Phase 2
Terminated NCT00321308 - Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer Phase 2
Terminated NCT01441128 - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Terminated NCT02961283 - Study of ASN003 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT00973310 - Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer Phase 2
Completed NCT00385996 - Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer Phase 2
Terminated NCT02775006 - Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma Phase 3
Completed NCT03232593 - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Terminated NCT02590003 - Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer Phase 2
Terminated NCT01514864 - Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation Phase 2
Completed NCT00070629 - CPG 7909 Injection in Non-Small Cell Lung Cancer Phase 2
Completed NCT02079636 - A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Phase 1
Completed NCT01079520 - Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC) N/A
Terminated NCT01115803 - A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors Phase 1
Completed NCT00861627 - Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation Phase 2
Completed NCT00923884 - Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
Recruiting NCT04389632 - A Study of SGN-B6A in Advanced Solid Tumors Phase 1
Terminated NCT03603652 - NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung N/A
Not yet recruiting NCT01131429 - A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Phase 2